Philips, Schering plan to partner in optical imaging

by Greg Freiherr

Philips and Schering are collaborating in breast imaging, using a
fluorescent dye developed by Schering and an experimental optical
scanner under construction by Philips. The two technologies will be
merged as part of a phase I clinical trial that could begin some time
next year.

The fluorescent dye omocianine will be injected into the bloodstream,
absorbing energy from a pulsed laser. The blood pool agent will then
fluoresce, transmitting light back to the Philips scanner for
reconstruction into images. The presence of abnormal vascular beds
apparent in the images will indicate tumors, according to Philips.

A commercial device is several years away, as the safety and efficacy
of the device and imaging agent must be documented to win FDA
approval for marketing in the U.S. The clinical trials planned for
next year will begin to provide that documentation.

In the meantime, Philips and Schering may expand their alliance to
cover other imaging technologies and contrast agents that might lead
to synergies, according to the companies. They have agreed to split
equally all research and development costs as well as all future
revenues from the contrast agents, medical equipment, and related
services related to this partnership.